Protective effect of cilostazol and rosuvastatin on acute kidney injury-induced lung injury using TNF-a and HIF-1a immunoreactivities

Materials and methods: A total of 35 female Sprague-Dawley rats were randomly divided into five groups (n=7). Median laparotomy and a 45-min bilateral kidney ischemia were performed. Oral medications were administered three days before the surgical intervention (20 mg/kg cilostazol, 10 mg/kg rosuvastatin, and 20 mg/kg cilostazol+10 mg/kg rosuvastatin). Lung tissue samples were extracted one day after surgery. Tumor necrosis factor-a (TNF-a) and hypoxiainduced factor-1a (HIF-1a) antibodies were used for immunohistochemical examinations of lung tissues cross-sections.

Results: TNF-a immunoreactivities in I/R+cilostazol, I/R+rosuvastatin and I/R+cilostazol+rosuvastatin groups were found to be decreased significantly, compared to I/R group (p<0.05). Lung TNF-a immunoreactivities in I/R+rosuvastatin, and I/R+cilostazol+rosuvastatin groups was found to be increased significantly, compared to control group (p<0.05). HIF-1a immunoreactivities in I/R+cilostazol, I/R+rosuvastatin, and I/R+cilostazol+rosuvastatin groups were found to be decreased significantly, compared to I/R group (p<0.05). HIF-1a immunoreactivites amoung I/R+cilostazol, I/R+rosuvastatin and I/R+cilostazol+rosuvastatin groups were found similar, compared to control group (p>0.05).

Conclusion: Cilostazol and rosuvastatin have prophylactic effects on kidney I/R injury-induced lung reperfusion injury. Their single or combined use for peripheral arterial diseases may be beneficial for patients on perioperative period.